Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis

Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis

Background: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been used to treat patients with diffuse large B-cell lymphoma (DLBCL) under National Health Insurance (NHI) scheme in Indonesia. This study aims to estimate its cost-effectiveness and budget impact. M...

Full description

Bibliographic Details
Main Authors: Armansyah, A. (Author), Khoe, L.C (Author), Megraini, A. (Author), Nadjib, M. (Author), Putri, S. (Author), Saldi, S.R.F (Author), Sari, E.R (Author), Sastroasmoro, S. (Author), Setiawan, E. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Cost-effectiveness
DLBCL
Lymphoma
Rituximab
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items